• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Gilead Sciences

Gilead Sciences

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Netflix is standout winner in the second quarter

    Netflix is standout winner in the second quarter

  2. UPDATE: Netflix is the standout winner in the second quarter

    UPDATE: Netflix is the standout winner in the second quarter

  3. China rejects Gilead's patent for $1,000-a-day drug

    China rejects Gilead's patent for $1,000-a-day drug

  4. Research and Markets: Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies

    Research and Markets: Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies

  5. Research and Markets: Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles

    Research and Markets: Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles

  6. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

  7. UPDATE: The six best sectors for 2015's second half

    UPDATE: The six best sectors for 2015's second half

  8. UPDATE: The six best sectors for 2015's second half

    UPDATE: The six best sectors for 2015's second half

  9. Research and Markets: Essential Thrombocythemia Pipeline Review, H1 2015

    Research and Markets: Essential Thrombocythemia Pipeline Review, H1 2015

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.